1.Different adjuvant chemotherapies for the retreatment patients with advanced primary hepatic ;carcinoma:an efficacy and survival analysis
Xihao YU ; Xinping LI ; Jianliang ZHOU ; Yongmei WANG ; Yongde CHENG ; Jianping WANG ; Gefang WANG
Cancer Research and Clinic 2016;28(9):608-610,615
Objective To study the significance of treating advanced primary hepatic carcinoma by using the different methods combined with chemotherapy. Methods One hundred and fifteen cases with advanced primary hepatic carcinoma were divided into 5 groups by accepting different chemotherapy: the groups of interventional-chemotherapy (group A, 40 cases), whole body hyperthermia combined with chemotherapy (group B, 16 cases), only chemotherapy (group C, 9 cases), local heat chemotherapy (group D, 26 cases), symptomatic supportive (group E, 24 cases) for comparing response rate (RR) and survival time between each other. Results The RR in group A,B,C were 30.5 % (12/40), 12.5 % (2/16), 11.1 % (1/9) respectively, and there was no significant difference among three groups (P>0.05). The mid-survival time of five groups were 7.7, 9.2, 7.9, 6.0, 4.7 months, and there was significant difference between group B and group E (P<0.05). The 0.5-, 1-, 2-year survival rate in group B were higher than those in group E with significant difference (81.2%vs. 29.1%, 37.5%vs. 12.5%, 12.5%vs. 0, all P<0.05). Conclusions The RR of only routine chemotherapy is low, while the RR of interventional-chemotherapy and local heat chemotherapy is high with non-prolonged survival time. Whole body hyperthermia combined with chemotherapy have active effects in helping to improve the efficacy and prolong the survival time in retreatment patients with advanced hepatic tumor.
2.Clinical study of intraperitoneal chemotherapy combined with whole body thermal therapy in the treatment of malignant seroperitoneum
Gefang WANG ; Chengli WU ; Chengyuan JIANG ; Xihao YU ; Lei WANG ; Qin ZHU
Journal of Clinical Medicine in Practice 2018;22(3):123-124,127
Objective To study the short-term efficacy and toxicity of intraperitoneal chemotherapy combined with thermotherapy in the treatment of malignant ascites.Methods A total of 60 patients were randomly divided into control group (30 cases) and study group (30 cases).The control group received intraperitoneal chemotherapy and was given chemotherapy drugs injecting after drainage of ascites,while the study group was given intraperitoneal chemotherapy combined with whole body thermal therapy.The short-term efficacy and toxicity were evaluated.Results The efficacy rate of life quality improvement in the study group was higher than that in the control group (90% vs.60%,P < 0.05).There was no significant difference between the two groups in toxicity (P >0.05).Conclusion Intraperitoneal chemotherapy combined with whole body thermal therapy in the treatment of malignant ascites has higher efficacy and tolerance than intraperitoneal chemotherapy alone.
3.Clinical study of intraperitoneal chemotherapy combined with whole body thermal therapy in the treatment of malignant seroperitoneum
Gefang WANG ; Chengli WU ; Chengyuan JIANG ; Xihao YU ; Lei WANG ; Qin ZHU
Journal of Clinical Medicine in Practice 2018;22(3):123-124,127
Objective To study the short-term efficacy and toxicity of intraperitoneal chemotherapy combined with thermotherapy in the treatment of malignant ascites.Methods A total of 60 patients were randomly divided into control group (30 cases) and study group (30 cases).The control group received intraperitoneal chemotherapy and was given chemotherapy drugs injecting after drainage of ascites,while the study group was given intraperitoneal chemotherapy combined with whole body thermal therapy.The short-term efficacy and toxicity were evaluated.Results The efficacy rate of life quality improvement in the study group was higher than that in the control group (90% vs.60%,P < 0.05).There was no significant difference between the two groups in toxicity (P >0.05).Conclusion Intraperitoneal chemotherapy combined with whole body thermal therapy in the treatment of malignant ascites has higher efficacy and tolerance than intraperitoneal chemotherapy alone.